Key Proteo develops a novel Immuno-SRM proteomic screening platform that detects low-abundance proteins to identify rare genetic disorders in newborns before symptoms manifest. This technology enables early intervention, reducing the time to diagnosis and the associated economic burden for families affected by these treatable conditions.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare genetic disorders remain undetected in newborns until symptoms manifest, leading to delayed diagnosis and irreversible or fatal outcomes. Traditional screening methods often fail to identify these low-abundance biomarkers, resulting in a diagnostic odyssey and significant economic burden for affected families.
Solution
Key Proteo offers an Immuno-SRM (Selected Reaction Monitoring) proteomic screening platform designed for early detection of treatable rare genetic disorders in newborns. The platform accurately quantifies low-abundance proteins from dried blood spot specimens, enabling early intervention and improved patient outcomes. Key Proteo's technology integrates with existing laboratory workflows, providing a rapid, scalable, and cost-effective solution for enhancing newborn screening programs in public health and CLIA laboratory settings. By identifying previously undetectable disorders, Key Proteo aims to reduce the time to diagnosis and alleviate the burden of disease for patients and their families.
Target Audience
Key Proteo's primary customers are public health laboratories, CLIA-certified laboratories, and newborn screening programs seeking to expand their testing capabilities for rare genetic disorders.
Features
- Immuno-SRM proteomic platform for accurate detection of low-abundance peptide biomarkers
- Rapid and scalable workflow suitable for high-throughput screening
- Cost-effective solution with low capital expense and reagent costs
- Compatible with dried blood spot specimens
- Seamless integration with existing mass spectrometry workflows
- Multiplex analysis capabilities for simultaneous detection of multiple biomarkers
- Expertly curated Immuno-SRM panels for specific rare genetic disorders